论文部分内容阅读
目的观察上皮性卵巢癌患者血清中miRNA-200c的表达及其与临床特征的关系。方法应用RTPCR法检测30例上皮性卵巢癌患者(观察组A)、良性上皮性卵巢肿瘤患者(观察组B)、健康志愿者(对照组)血清中miRNA-200c的表达,并比较miRNA-200c在上皮性卵巢癌患者不同FIGO分期、病理类型、分化程度、淋巴结转移状态中的表达。结果观察组A、观察组B及对照组中miRNA-200c表达依次为(2.891±0.183),(1.121±0.126),(0.431±0.069),观察组A miRNA-200c相对表达量明显高于观察组B及对照组,观察组B明显高于对照组,差异均有统计学意义(P<0.05)。在观察组A中,miRNA-200c在卵巢子宫内膜样癌中高表达,随着FIGO分期的进展、分化程度的降低,miRNA-200c的表达呈下调趋势。淋巴结转移阳性的病例中,miRNA-200c表达也明显下调,以上差异均有统计学意义(P<0.05)。结论 miRNA-200c在上皮性卵巢癌的发生、发展的分子机制中可能具有类似致癌基因和抑癌基因的双重性作用。
Objective To investigate the expression of miRNA-200c in serum of patients with epithelial ovarian cancer and its relationship with clinical features. Methods The expression of miRNA-200c in serum of 30 patients with epithelial ovarian cancer (observation group A), benign epithelial ovarian tumor (observation group B) and healthy volunteers (control group) was detected by RTPCR method and compared with that of miRNA-200c In epithelial ovarian cancer patients with different FIGO staging, pathological type, degree of differentiation, lymph node metastasis of the expression. Results The expression of miRNA-200c in observation group A, observation group B and control group were (2.891 ± 0.183) and (1.121 ± 0.126) and (0.431 ± 0.069) respectively, and the relative expression of miRNA-200c in observation group was significantly higher than that in observation group B and control group, observation group B was significantly higher than the control group, the difference was statistically significant (P <0.05). In observation group A, miRNA-200c was overexpressed in ovarian endometrioid carcinoma. With the progress of FIGO stage, miRNA-200c expression was down-regulated. The expression of miRNA-200c was also significantly down-regulated in cases with positive lymph node metastasis, all of which were statistically significant (P <0.05). Conclusion The molecular mechanism of miRNA-200c may be similar to that of oncogenes and tumor suppressor genes in the pathogenesis of epithelial ovarian cancer.